Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Melanoma 65Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 52Lung Neoplasms 51Triple Negative Breast Neoplasms 47Neoplasm Metastasis 45Breast Neoplasms 42Neoplasms 39Colorectal Neoplasms 34Carcinoma, Renal Cell 30Head and Neck Neoplasms 29Endometrial Neoplasms 28Ovarian Neoplasms 27Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 21Stomach Neoplasms 17Carcinoma 16Pancreatic Neoplasms 15Uterine Cervical Neoplasms 14Esophageal Neoplasms 13Brain Neoplasms 13Recurrence 12Sarcoma 11Hodgkin Disease 11Carcinoma, Squamous Cell 11Carcinoma, Hepatocellular 11Cholangiocarcinoma 10Skin Neoplasms 9Esophageal Squamous Cell Carcinoma 9

Interventions

tremelimumab 2pembrolizumab 2Nivolumab 2Carboplatin 2poly ICLC 1osimertinib 1lenvatinib 1durvalumab 1cemiplimab 1balstilimab 1Vascular Endothelial Growth Factor A 1Peptides 1Pemetrexed 1Paclitaxel 1Ipilimumab 1Docetaxel 1Blood Specimen Collection 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × pembrolizumab × 90 days × Clear all
NCT04305054 2026-05-28

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
335 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Active not recruiting
400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡